The cost effectiveness of vaccinating against Lyme disease

Emerging Infectious Diseases

Volumn 5, Issue 3, 1999, Pages 321-328

  Meltzer, Martin I ^a,b   Dennis, David T ^a   Orloski, Kathleen A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYME DISEASE VACCINE; UNCLASSIFIED DRUG; VACCINE;

BACTERIAL OUTER MEMBRANE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE POLICY; INCIDENCE; LYME DISEASE; MEDICAL DECISION MAKING; PUBLIC HEALTH; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VACCINATION;

EID: 0033036176     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0503.990302     Document Type: Review

References (50)

1. Centers for Disease Control and Prevention. Lyme disease - United States, 1996. MMWR Morb Mortal Wldy Rep 1997;46:531-5.
2. Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringner A. Elmrud J, et al. An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 1995;333:1319-24.
3. Strle F, Stantic-Pavlinic M. Lyme disease in Europe [letter, comment]. N Engl J Med 1996;334:803.
4. Cartter ML, Mshar P, Hadler JL. The epidemiology of Lyme disease in Connecticut. Conn Med 1989;53:320-3.
5. Ginsberg HS. Geographical spread of Ixodes dammini and Borrelia burgdorferi. In: Ginsberg HS, editor. Ecology and environmental management of Lyme disease. New Brunswick (NJ): Rutgers University Press; 1993. p. 63-82.
6. White DJ, Chong HG, Benach JL, Bosler EM, Meldrum SC, Means RG, et al. The geographic spread and temporal increase of the Lyme disease epidemic. JAMA 1991;266:1230-6.
7. Dennis DT. Lyme disease. Dermatol Clin 1995;13:537-51.
8. Schwartz BS, Goldstein MD, Childs JE. Antibodies to Borrelia burgdorferi and tick salivary gland proteins in New Jersey outdoor workers. Am J Public Health 1993;83:1746-8.
9. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998;339;209-15.
10. Sigal HL, Zahradnik JM, Levin P, Patella SJ, Bryant G, Haselby R, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998;339;216-22.
11. Centers for Disease Control and Prevention. Notice to readers: availability of Lyme disease vaccine. MMWR Morb Mortal Wkly Rep 1999;48:35-6,43.
12. Snider DE, Holtgrave DR, Duñet DO. Decision analysis. In: Haddix AC, Teutsch SM, Shaffer PA, Duñet DO, editors. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: Oxford University Press; 1996. p. 27-46.
13. Palisade Corporation. Guide to using @Risk (Windows version). Newfield (NY): Palisade Corporation; 1996.
14. Dittus RS, Roberts SD, Wilson JR. Quantifying uncertainty in medical decisions. J Am Coll Cardiol 1989;14:23A-8.
15. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making 1986;6:85-92.
16. Dobilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985;5:157-77.
17. Telford SR, Kantor FS, Lobet Y, Barthold SW, Spielman A, Flavell RA, et al. Efficacy of human Lyme disease vaccine formulations in a mouse model. J Infect Dis 1995;171:1368-70.
18. De Silva AM, Telford SR III, Brunet LR, Barthold SW, Fikrig E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 1996;183:271-5.
19. Straubinger RK, Chang YF, Jacobson RH, Appel MJG. Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. J Clin Microbiol 1995;33:2745-51.
20. Philipp MT, Lobet Y, Bohm RP, Conway MD, Dennis VA, Desmons P, et al. Safety and immunogenicity of recombinant outer surface protein A (OspA) vaccine formulations in the rhesus monkey. Journal of SpirochetalTickborne Disease 1996:67-79.
21. Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP. Safety and immunogenicity of a recombinant outer surface protein A Lyme Vaccine. JAMA 1994;271:1764-8.
22. Schoen RT, Meurice F, Brunet CM, Cretella S, Krause DS, Craft JE, et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis 1995;172:1324-9.
23. Padilla ML, Callister SM, Schell RF, Bryant GL, Jobe DA, Loverich SD, et al. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. J Infect Dis 1996;174:739-46.
24. Steere AC. Lyme disease. N Engl J Med 1989;321:586-96.
25. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, et al. Treatment of early Lyme disease. Am J Med 1992;92:396-403.
26. Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995;39:661-7.
27. Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997;337:289-94.
28. Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH, Liu NY, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994;37:878-88.
29. Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites: a cost-effectiveness analysis. N Engl J Med 1992;327:534-41.
30. Nichol G, Dennis DT, Steere AC, Lightfood R, Wells G, Shea B, et al. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1998;128:37-48.
31. Lightfoot RW, Luft BJ, Rahn DW, Steere AC, Sigal LH, Zoschke DC, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serological result for Lyme disease. Ann Intern Med 1993;119:503-9.
32. Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP, et al. The long-term clinical outcomes of Lyme disease. Ann Intern Med 1994;121:560-7.
33. Alpert B, Esin J, Sivak SL, Wormser GP. Incidence and prevalence of Lyme disease in a suburban Westchester County community. New York State Journal of Medicine 1992;92:5-8.
34. Steere AC, Taylor E, Wilson ML, Levine JF, Spielman A. Longitudinal assessment of the clinical and epidemiological features of Lyme disease in a defined population. J Infect Dis 1986;154:295-300.
35. Kaslow RA, Samples CL, Simon DG, Lewis JN Occurrence of erythema chronicum migrans and Lyme disease among children in two noncontiguous Connecticut counties. Arthritis Rheum 1981;24:1512-6.
36. Hanrahan JP, Benach JL, Coleman JL, Bosler EM, Morse DL, Cameron DJ, et al. Incidence and cumulative frequency of endemic Lyme disease in a community. J Infect Dis 1984;150:489-95.
37. Lastavica CC, Wilson ML, Berardi VP, Spielman A, Deblinger RD. Rapid emergence of a focal epidemic of Lyme disease in costal Massachusetts. N Engl J Med 1989;320:133-7.
38. Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther 1998;20:993-1008.
39. Evans M, Hastings N, Peacock B. Statistical distributions. 2nd ed. New York: John Wiley; 1993.
40. Statistical abstract of the United States. 117th ed. Washington: U.S. Bureau of the Census; 1997.
41. Meltzer MI, Teutsch SM. Setting priorities for health needs, managing resources. In: Teutsch SM, Stroup DF, editors. Quantitative solutions to public health problems. New York: Oxford University Press; 1998. p. 123-49.
42. Haddix AC, Shaffer PA. Cost-effectiveness analysis In Haddix AC, Teutsch SM, Shaffer PA, Duñet DO, editors Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: Oxford University Press; 1996. p. 103-29.
43. The Federal Register. Vol 61; no. 170; 1996 Aug 30, 46301-2.
44. Productivity loss tables [Appendix I]. In: Haddix AC, Teutsch SM, Shaffer PA, Duñet DO, editors. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York; Oxford University Press; 1996 p. 187-92.
45. Fix AD, Strickland T, Grant J. Tick bites and Lyme disease in an endemic setting. JAMA 1998;279:206-10
46. Centers for Disease Control and Prevention. Lyme disease - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:531-5.
47. Coyle BS, Strickland GT, Liang YY, Peña C, McCarter R, Israel E. The public health impact of Lyme disease in Maryland. J Infect Dis 1996;173:1260-2.
48. Meek JL, Roberts CL, Smith EV, Cartter ML Underreporting of Lyme disease by Connecticut physicians, 1992. Journal of Public Health Management Practice 1996;2:61-5.
49. Centers for Disease Control and Prevention. Prevention of Lyme disease through active immunization recommendations of the Advisory Committee on Immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. In press 1999.
50. Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st century: a tool for decision making Washington: National Academy Press. In press 1999.